Axial Spondyloarthritis
Conditions
Brief summary
This is an observational study using Inertial Measurement Unit (IMU) sensors to measure the effects of biological therapy on spinal mobility and function in axial spondyloarthritis. Participants will undergo MRI scans before and after therapy in parallel to the sensor tests to establish correlation between changes in inflammatory signs and changes in spinal mobility.
Detailed description
We will study 20 participants with active axial spondyloarthritis (axSpA) who are about to start biologic therapy as part of routine care. In brief, we will carry out the following assessments before and after therapy: 1. MRI of spine and Sacroiliac (SI) joints - modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) scoring 2. Record standard Patient recorded outcomes (PROs): Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Global (BASG), Bath Ankylosing Spondylitis Metrology Index (BASMI), Bath Ankylosing Spondylitis Functional Index (BASFI), Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Disease Activity Score Health Index (ASAS-HI), Euroquol 3 level health assessment (EQ5D-3L), work productivity and activity impairment questionnaire (WPAI), Short QUestionnaire to ASsess Health enhancing physical activity (SQUASH), 3. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) 4. IMU sensor tests in clinic for range of motion (ROM) in cervical, thoracic and lumbar spine. 5. IMU sensor tests at home for standardised function testing
Interventions
DEVICEIMU sensor test
Measurement of maximum range of movement in the spine; Ambulatory observational data while performing standardised functional tests
Sponsors
University of Ulster
Western Health and Social Care Trust
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Inclusion criteria
1. Diagnosis of axial spondyloarthritis fulfilling ASAS classification criteria. 2. Age ≥18 years old and \<80 years. 3. Fulfilment of local criteria for biologic therapy for axSpA. 4. The subjects should be able to read, write, understand and complete study questionnaires. 5. Each subject must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study.
Exclusion criteria
1. Safety contra-indication for biologic drug therapy. 2. Severely restricted hip movement (less than 20 degrees rotation in either hip). 3. History of previous clinical (symptomatic) vertebral fracture. 4. History of previous spinal surgery. 5. History of previous hip replacement surgery. 6. Major scoliosis deformity (in the opinion of the investigator). 7. Safety contra-indication for MRI assessment. 8. Previous biologic agent within 2 months. 9. Pregnant or breast-feeding women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in composite IMU sensor based metrology index (IMU-ASMI) | 4 months | Change in AxSpA metrology index based on sensor tests of Range of Movement (i.e. spinal mobility). Scale 0-10, with 10 being severe loss of spinal mobility. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) | 4 months | Change in axSpA disease activity. BASDAI scale 0-10, 10 representing high disease activity |
| Change in Assessment of Spondyloarthritis International Society Response Criteria (ASAS20) | 4 months | Change in axSpA disease activity response - 20% improvement is regarded as minimum improvement in at least three of Patient global assessment, Pain assessment, BASFI and Inflammation (last two questions of BASDAI) |
| Change in Bath Ankylosing Spondylitis Metrology Index (BASMI) | 4 months | Change in traditional metrology index of spinal mobility. Scale 0-10, with 10 being severe loss of spinal mobility. |
| Change in Bath Ankylosing Spondylitis Functional Index (BASFI) | 4 months | Change in traditional questionnaire function assessment 0-10 scale, 10 representing a high degree of functional impairment |
| Change in Sit to Stand Test Scores | 4 months | Change in standardised function score. Time taken to complete 5 sit to stand actions from a seated position on a chair at standard height. |
| Change in modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) | 4 months | Change in MRI score of inflammation. Range 0-72 the sum of scores for 24 vertebral edges in the lumbar and cervical regions, higher represents more spinal damage. |
Countries
United Kingdom
Contacts
Primary ContactDawn Small
Backup ContactAaron Peace, MD
Outcome results
None listed